(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.
The AIM-traded firm said recruitment for the study had resumed, with two patients scheduled to be treated in October and all remaining patients expected to be treated by the end of the year.
Given that, the company said it now expected to present early efficacy data on the expansion cohort in the first quarter of 2022.
It added that it remained on track for advancing the programme into the next clinical trial by the end of next year.
"We are pleased to be back on track, having received the required regulatory approvals and now recruiting in all our target geographies for our phase 2a clinical trial of our hRPC cell therapy candidate in retinitis pigmentosa," said chief executive officer Olav Hellebø.
At 1011 BST, shares in ReNeuron Group were up 1.08% at 93.5p.
Reneuron (RENE)17 May 2024 19:59
IN BRIEF: ReNeuron administrators in talks with potential investors
ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Says Mark Smith and Stephen Cork of Cork Gully LLP, joint admin...